Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 18, 2006
Grant Date -
N/A
app pub date -
Dec 28, 1999
filing date -
Dec 28, 1998
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
This invention relates to the use of recombinant adeno-associated virus (rAAV) vectors to transduce cardiomyocytes in vivo by infusing the rAAV into a coronary artery or coronary sinus. rAAV infection is not associated with detectable myocardial inflammation or myocyte necrosis. Thus, rAAV is a useful vector for the stable expression of therapeutic genes in the myocardium and can be used to deliver genes for inducing angiogenesis, inhibiting angiogenesis, stimulating cell proliferation, inhibiting cell proliferation and/or treating or ameliorating other cardiovascular conditions.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully